Jump to content

Roberto Ferrari (cardiologist)

Add links
From Wikipedia, the free encyclopedia

This is the current revision of this page, as edited by Citation bot (talk | contribs) at 14:08, 2 November 2024 (Altered doi-broken-date. | Use this bot. Report bugs. | #UCB_CommandLine). The present address (URL) is a permanent link to this version.

(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)
Roberto Ferrari
Born (1950-06-10) June 10, 1950 (age 74)
OccupationCardiologist

Roberto Ferrari (born 10 June 1950) is an Italian cardiologist who holds the position of Emeritus Professor at the University of Ferrara,[1][2][3] where besides he was the chair of the Cardiology in the School of Medicine until the 2019–2020 academic year.

Ferrari has served as the Director of the Cardiovascular Centre of the University of Ferrara, the Director of Cardiology at the St. Anna University Hospital of Ferrara, and the Director of the Centre of Cardiovascular Research "S. Maugeri".[2][4] Ferrari is past President of the European Society of Cardiology (ESC).

Life

[edit]

Ferrari was born in La Spezia, Italy. He is the only son of a textile merchant. He was encouraged by his cousin, a biochemist, Anna Maria Sechi, to study medicine.[5][6][7]

Education

[edit]

Ferrari graduated with distinction from the Bologna School[8] of Medicine in 1974.[2][3][5][9][10][6] Upon graduation, Professor Ferrari went on to complete specialized post graduate studies at both the School of Cardiology through the University of Parma (1974-1976), and the School of Radiology through the University of Bologna (1977-1980).[2][3][5][9][6] Driven by a keen interest in research, Professor Ferrari proceeded to complete his PhD degree in field of cardiac metabolism at the Cardiothoracic Institute of the National Heart Hospital through the University of London (1980-1982).[2][3][5][9][10][6] He served as an Honorary Assistant Research Fellow at the National Heart Hospital in London from 1978 to 1989, and as a Senior Research Fellow at the Rayne Institute of St. Thomas’ Hospital in London (1989-1996).[10]

Career

[edit]

Ferrari has contributed scientific findings targeted at characterizing the molecular mechanisms of the ischemic and failing myocardium, dedicating himself to improving the clinical treatment of myocardial ischemia and heart failure, while placing a particular emphasis on interdisciplinary and collaborative studies throughout his career.[2][3][5][9][10]

Ferrari holds the position of Emeritus Professor at the University of Ferrara.[1][2][3] His academic career path development follows his initial appointment to the position of associate professor in Cardiology at the University of Brescia in 1987 and then at the University of Ferrara in 1998.[10] In 2000, Professor Ferrari was appointed to the position of Full Professor in Cardiology as well as the Director of the Cardiovascular Centre of the University of Ferrara and Director of Cardiology at the St. Anna University Hospital of Ferrara.[2][3][5][9][4][10] In addition to his current position as Emeritus Professor, Ferrari is presently the Scientific Director of Medical Trial Analysis, an academic Clinical Research Organization (CRO).[11] He founded the European Heart for Children (EHC), established during his presidency of the European Society of Cardiology (ESC). As a non-profit organization, the EHC aims to cure children born with congenital heart diseases in underdeveloped countries. Since its formation, the EHC has effectively conducted nearly 30 missions, examined, diagnosed, and treated over 2200 children, with 349 being successfully operated on, and trained numerous cardiologists and cardiac surgeons around the world. Moreover, the EHC has built a pediatric cardiovascular surgeon training center in Nigeria and successfully constructed a Pediatric Unit in Syria, with the third facility in Morocco currently in progress.[5][7][12][13][14]

Ferrari has held positions held in several cardiological organizations: Founder and President of the European Heart for Children (EHC) from 2010 to 2018;[2][5][7][13] Member of the European Society of Cardiology (ESC) Committee for Practice Guidelines from 2012 to 2014;[2][15] President of the European Society of Cardiology (ESC) from 2008 to 2010;[2][3][5][9][16][4] Vice President & Chairman of the ESC Associations, Councils & Working Groups 2004–2006;[2][3][6] Executive Board Member and Chairman of the ESC Education Committee 2002–2004;[2][3][6] President of the World Section of the International Society for Heart Research (ISHR) from 2004 to 2007 and Treasurer from 1994 to 2002.[2][3][6][17] He was Chairman of the ESC Working Group on Cellular Biology 1994–1996,[2][3][6] Chairman of the EURObservational Research Program (EORP) of the European Society of Cardiology,[2][7][18] Director of the School for Clinical and Epidemiologic Researchers,[12] Board member of the World Heart Federation as a representative of Italy[2][19] and founder and president of the scientific foundation Fondazione Anna Maria Sechi per il Cuore (FASC) in honor of his cousin.[20][21]

Editorial boards

[edit]

He is Editor-in-Chief of the European Heart Journal Supplements: the Heart of the Matter[2][22][23] and Editor of Dialogues in Cardiovascular Medicine.[2][6]

His contributions to the field of cardiology include several books, over 800 published peer-reviewed papers, citation numbers nearing 50 000, and an H-index that is close to 90.[24][25][26]

Honors and awards

[edit]
  • Kobe City Award (1992)[2]
  • Gold Medal of International Society for Heart Research World Section (1999)[2]
  • Gold Medal of the European Society of Cardiology (2010)[2]
  • Andreas Gruntzig Award of the Swiss Society of Cardiology (2013)[2][27]
  • Professor Emeritus of the University of Ferrara (2022)[1]
  • Lifetime Achievement Award of the Heart Failure Association of the European Society of Cardiology (2022)[28][29]

Scientific contributions

[edit]

Ferrari's scientific contributions are recognized in both the field of basic and translational medicine, as well as clinical research. Ferrari's extensive research contributions have led to significant changes in cardiology practice guidelines and resulted in the successful registration of related pharmaceutical products.[30][31]

Translational medicine

[edit]

Ferrari's contributions in basic and Medicina traslazionale encompass 4 distinct areas:

  • Illustrating the dangers pertaining to the neuroendocrine activation in untreated patients suffering from severe heart failure and providing an evidenced scientific basis for anti-neuroendocrine therapy using ACEi, beta blockers, and mineral corticoid antagonists. Studies conducted in India, at the PGI Institute, Chandigarh, Punjab in collaboration with Prof I. Anand, Prof P. Harris, P. Poole Wilson.[32][33][34][35][36][37][38][39][40]
  • Understanding the mechanisms and clinical relevance of the hibernating myocardium, provided the suggestion of using echocardiography with dobutamine as a test for cardiac surgery in patients with severe reduction of ejection fraction. Studies conducted in collaboration with Prof S. Rahimtoola.[41][42][43][44][45][46][47][48][49][50][51]
  • Elucidating the role of coronary arteries as well as endothelial apoptosis and regeneration clarified the superiority of ACEi vs angiotensin antagonists to protect the heart against progression of atherosclerosis.[52][53][54][55][56][57][58][59][60][61]
  • Comprehending the functional roles of the life and death cycle, and that failing myocytes lead to the pathophysiological understanding of remodeling. Presented future investigative opportunities related to the Herceptin drug mechanism of action of, marking the start of the Cardio-oncology era.[62][63][64][65][66][67]

Clinical medicine

[edit]

Ferrari's contributions in clinical medicine have led to changes in cardiology practice guidelines and facilitated the registration of pharmaceutical products in 5 distinct areas:

  • EUROPA (The European trial On reduction of cardiac events with Perindopril in stable coronary Artery disease) trial has demonstrated the usefulness of perindopril in reducing the progression of coronary atherosclerosis. The use thereof has been endorsed by the European Medicines Agency (EMA) and by extension the therapeutic use of perindopril in the treatment of hypertension to ischemic heart disease is both recognized and recommended in American and European guidelines alike.[68][69][70]
  • BEAUTIFUL (Morbidity-mortality Evaluation of the If inhibitor ivabradine in patients with coronary disease and left-ventricular dysfunction) trial demonstrates the effects of ivabradine in patients with ischemic heart disease and left ventricular dysfunction. The outcomes of this trial facilitated the successful registration of ivabradine through EMA for treatment of ischemic heart disease in patients intolerant to beta blocker therapy with a heart rate of > 70 b/min.[71][72][73][74]
  • SHIFT (Systolic Heart failure treatment with the IF inhibitor ivabradine Trial) showed the benefits of ivabradine in heart failure patients and allowed the registration at EMA and FDA of perindopril in heart failure patients with heart rate > 70 b/min and its indication in the American and European guidelines.[75][76][77][78]
  • SIGNIFY (Study assessing the morbidity-mortality benefits of the If inhibitor ivabradine in patients with coronary artery disease) contributed to the understanding of ivabradine according to the left ventricular function. This has led in increased indication precision for treatment of ischemic heart diseases.[79][80][81][82]
  • ATPCI (efficacy and safety of Trimetazidine in patients with angina pectoris having been treated by percutaneous coronary intervention) trial demonstrated that trimetazidine does not improve either the symptoms or outcomes of post-angioplasty patients with ischemic heart disease. Trimetazidine indications observed in this pathology are currently under EMA directed revision.[83]

Steering committees

[edit]

Ferrari has been on the steering committees of several multicenter trials as chairman of the following trials: PREAMI, EUROPA, STRATEGY, MULTI-STRATEGY, 3T2R, Beautiful, Shift, Signify, Modify, START-IF, ATPCI.[2][9] And as the Executive Committee Member of the following trials: SENIORS, PACMAN, Clarify, COMPOSE, RELAX-AHF 2.[2]

Bibliography

[edit]
  • Ferrari, R.; Katz, A.; Shug, A.; Visioli, O. (1984). Myocardial Ischemia and Lipid Metabolism. New York: Plenum Press. ISBN 978-1-4684-4865-8.
  • Ferrari, R.; Di Mauro, S.; Sherwood, G. (1992). L-carnitine and Its Role in Medicine: From Function to Therapy. London: Academic Press. ISBN 978-0122539404.
  • Ferrari, R.; Opie, L. H. (1992). Atlas of the Myocardium. New York: Raven Press. ISBN 978-0881678703.
  • Fox, K.; Ferrari, R. (2005). Heart Rate Management in Stable Angina. Taylor & Francis. ISBN 978-1841845944.
  • Ferrari, R.; Mugelli, A.; Tavazzi, L.; Zaza, A. (2007). Il ritmo della vita : Cuore e frequenza cardiaca fra arte, cultura e scienza (in Italian). Roma: Viviani Editore. ASIN B00U3REW0O.
  • Ferrari, R.; Florio, C. (2010). The European Cook Book: Healthy diets, healthy hearts. European Society of Cardiology. ISBN 978-2953789805.
  • Ferrari, R.; Ponikowski, P. (2012). Moving Forward in Management of Ischemic Cardiomyopathy. Paris: Springer. ISBN 978-2-8178-0277-0.

References

[edit]
  1. ^ a b c "Cerimonie | Unife celebra i suoi Professori Emeriti e Onorari". Università degli studi di Ferrara (in Italian). Retrieved 2022-07-01.
  2. ^ a b c d e f g h i j k l m n o p q r s t u v w x y "6th Iranian Joint Cardiovascular Congress - Roberto FERRARI". 2018ijcc.iha.org.ir. Retrieved 2022-07-01.
  3. ^ a b c d e f g h i j k l "Cardiology & Diabetes 2010 | Speaker biographies". The Lancet. doi:10.1016/presentation.2014.12.08.1218 (inactive 1 November 2024). Retrieved 2022-07-01.{{cite web}}: CS1 maint: DOI inactive as of November 2024 (link)
  4. ^ a b c HealthManagement.org. "Radiology Management, ICU Management, Healthcare IT, Cardiology Management, Executive Management". HealthManagement. Retrieved 2022-07-01.
  5. ^ a b c d e f g h i Kirby, Tony (August 2010). "Roberto Ferrari: outgoing ESC President and dynamic cardiologist". The Lancet. 376 (9740): 507. doi:10.1016/s0140-6736(10)61240-8. ISSN 0140-6736. PMID 20709220. S2CID 36881267.
  6. ^ a b c d e f g h i Publishing, BIBA (2011-04-17). "Roberto Ferrari". Cardiovascular News. Retrieved 2022-07-01.
  7. ^ a b c d Ozkan, Judy (2020-12-14). "Roberto Ferrari". European Heart Journal. 41 (47): 4463–4465. doi:10.1093/eurheartj/ehaa903. ISSN 0195-668X. PMID 33128059.
  8. ^ Bologna School
  9. ^ a b c d e f g Lüscher, Thomas F. (March 2009). "CardioPulse: sensing the cardiovascular world". European Heart Journal. 30 (5): 517–523. doi:10.1093/eurheartj/ehp059. ISSN 1522-9645. PMID 19252223.
  10. ^ a b c d e f "CardioPulse Articles". European Heart Journal. 31 (17): 2067–2074. 2010-09-01. doi:10.1093/eurheartj/ehq260. ISSN 0195-668X.
  11. ^ "MTA - Medical Trials Analysis - Contract Research Organization (CRO)". MTA - Medical Trials Analysis - Contract Research Organization (CRO). Retrieved 2022-07-01.
  12. ^ a b MacDonald, I.; Pasupati, S. (July 2010). "CardioPulse Articles". European Heart Journal. 31 (14): 1663–1671. doi:10.1093/eurheartj/ehq191. ISSN 1522-9645. PMID 20630896.
  13. ^ a b "Home". www.europeanheartforchildren.com. Retrieved 2022-07-01.
  14. ^ Ferrari, Roberto; Frigiola, Alessandro (2018-10-01). "Are all children born the same?". European Heart Journal. 39 (37): 3411–3415. doi:10.1093/eurheartj/ehy489. hdl:11392/2411180. ISSN 0195-668X. PMID 30102346.
  15. ^ "ESC Clinical Practice Guidelines Committee (CPG Committee)". www.escardio.org. Retrieved 2022-07-01.
  16. ^ "A brief history of the ESC". www.escardio.org. Retrieved 2022-07-01.
  17. ^ "ISHR Presidents Gallery". Retrieved 2022-07-04.
  18. ^ "Past Presidents' Committee". www.escardio.org. Retrieved 2022-07-04.
  19. ^ "World Heart Federation Annual Report 2011". Retrieved 2022-07-04.
  20. ^ "Ridere protegge cuore come sport e farmaci". www.pharmapro.ch. Retrieved 2022-07-04.
  21. ^ "NASCE LA FONDAZIONE "ANNA MARIA SECHI PER IL CUORE" – Medinews" (in Italian). Retrieved 2022-07-04.
  22. ^ "European Heart Journal Supplements | Oxford Academic". OUP Academic. Retrieved 2022-07-04.
  23. ^ "EHJ Supplements". www.escardio.org.
  24. ^ "ORCID". orcid.org. Retrieved 2022-07-04.
  25. ^ "Scopus preview - Ferrari, Roberto - Author details - Scopus". www.scopus.com. Retrieved 2022-07-04.
  26. ^ "Top Italian Scientists". topitalianscientists.org. Retrieved 2022-07-04.
  27. ^ "CardioPulse Articles". European Heart Journal. 34 (7): 477–482. 2013-02-14. doi:10.1093/eurheartj/ehs430. ISSN 0195-668X.
  28. ^ "ESC 365 - The cardiology knowledge hub". esc365.escardio.org. Retrieved 2022-07-04.
  29. ^ "National Heart Failure Societies Summit Programme. 2022" (PDF). Retrieved 2022-07-04.
  30. ^ Endorsed by the European Society of Intensive Care Medicine (2005-01-25). "Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: The Task Force on Acute Heart Failure of the European Society of Cardiology". European Heart Journal. 26 (4): 384–416. doi:10.1093/eurheartj/ehi044. hdl:10400.16/493. ISSN 0195-668X. PMID 15681577.
  31. ^ Authors/Task Force Members; Konstantinides, Stavros V.; Torbicki, Adam; Agnelli, Giancarlo; Danchin, Nicolas; Fitzmaurice, David; Galiè, Nazzareno; Gibbs, J. Simon R.; Huisman, Menno V.; Humbert, Marc; Kucher, Nils (2014-11-14). "2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism". European Heart Journal. 35 (43): 3033–3080. doi:10.1093/eurheartj/ehu283. ISSN 1522-9645. PMID 25173341.
  32. ^ Ananad, I.S.; Veall, N.; Kalra, G.S.; Ferrari, R.; Sutton, G.; Lipkin, D.; Harris, P.; Poole-Wilson, P.A. (1989-05-01). "Treatment of heart failure with diuretics: body compartments, renal function and plasma hormones". European Heart Journal. 10 (5): 445–450. doi:10.1093/oxfordjournals.eurheartj.a059508. ISSN 1522-9645. PMID 2668005.
  33. ^ Anand, I S; Ferrari, R; Kalra, G S; Wahi, P L; Poole-Wilson, P A; Harris, P C (1989-08-01). "Edema of cardiac origin. Studies of body water and sodium, renal function, hemodynamic indexes, and plasma hormones in untreated congestive cardiac failure". Circulation. 80 (2): 299–305. doi:10.1161/01.CIR.80.2.299. ISSN 0009-7322. PMID 2752558.
  34. ^ Agnoletti, G.; Panzali, A. F.; Cornacchiari, A.; De Giuli, F.; Ferrari, R. (Sep 1990). "Effects of prolonged infusions of atrial natriuretic peptide and isoproterenol on the mechanical and endocrine function of isolated atria". Cardioscience. 1 (3): 217–223. ISSN 1015-5007. PMID 2151714.
  35. ^ Anand, Inder S.; Gurden, Jane; Wander, Gurpreet S.; O'Gara, Peter; Harding, Sian E.; Ferrari, Roberto; Cornacchiari, A.; Panzali, A.; Wahi, Purshotam L.; Poole-Wilson, Philip A. (Jan 1991). "Cardiovascular and hormonal effects of calcitonin gene-related peptide in congestive heart failure". Journal of the American College of Cardiology. 17 (1): 208–217. doi:10.1016/0735-1097(91)90729-S. PMID 1987228. S2CID 29615207.
  36. ^ Curello, S; Ceconi, C; Degiuli, F; Cargnoni, A; Alfieri, O; Pardini, A; Marzollo, P; Mastropiero, R; Ferrari, R (1991). "Time course of human atrial natriuretic factor release during cardiopulmonary bypass in mitral valve and coronary artery diseased patients". European Journal of Cardio-Thoracic Surgery. 5 (4): 205–210. doi:10.1016/1010-7940(91)90031-E. PMID 1829375.
  37. ^ Anand, I S; Ferrari, R; Kalra, G S; Wahi, P L; Poole-Wilson, P A; Harris, P C (Jun 1991). "Pathogenesis of edema in constrictive pericarditis. Studies of body water and sodium, renal function, hemodynamics, and plasma hormones before and after pericardiectomy". Circulation. 83 (6): 1880–1887. doi:10.1161/01.CIR.83.6.1880. ISSN 0009-7322. PMID 2040040. S2CID 1872909.
  38. ^ Ferrari, R.; Panzali, A.F.; Poole-Wilson, P.A.; Anand, S. (Oct 1991). "Plasma CGRP-like immunoreactivity in treated and untreated congestive heart failure". The Lancet. 338 (8774): 1084. doi:10.1016/0140-6736(91)91944-P. PMID 1681388. S2CID 33395755.
  39. ^ Mantri, R. R.; Bajaj, R.; Radhakrishnan, S.; Sinha, N.; Bidwai, P. S. (Apr 1992). "Pathogenesis of edema in constrictive pericarditis". Circulation. 85 (4): 1634–1635. doi:10.1161/circ.85.4.1555304. ISSN 0009-7322. PMID 1555304.
  40. ^ Anand, I S; Chandrashekhar, Y; Ferrari, R; Sarma, R; Guleria, R; Jindal, S K; Wahi, P L; Poole-Wilson, P A; Harris, P (Jul 1992). "Pathogenesis of congestive state in chronic obstructive pulmonary disease. Studies of body water and sodium, renal function, hemodynamics, and plasma hormones during edema and after recovery". Circulation. 86 (1): 12–21. doi:10.1161/01.CIR.86.1.12. ISSN 0009-7322. PMID 1617764. S2CID 52868499.
  41. ^ Ferrari, R.; La Canna, G.; Giubbini, R.; Alfieri, O.; Visioli, O. (Jun 1992). "Hibernating myocardium in patients with coronary artery disease: Identification and clinical importance". Cardiovascular Drugs and Therapy. 6 (3): 287–293. doi:10.1007/BF00051152. ISSN 0920-3206. PMID 1637735. S2CID 3046148.
  42. ^ Ferrari, R.; La Canna, G.; Giubbini, R.; Visioli, O. (1992). "Stunned and hibernating myocardium: possibility of intervention". Journal of Cardiovascular Pharmacology. 20 (Suppl 5): S5–13. doi:10.1097/00005344-199212061-00002. ISSN 0160-2446. PMID 1282614.
  43. ^ La Canna, Giovanni; Alfieri, Ottavio; Giubbini, Rafaele; Gargano, Mario; Ferrari, Roberto; Visioli, Odoardo (Mar 1994). "Echocardiography during infusion of dobutamine for identification of reversible dyfunction in patients with chronic coronary artery disease". Journal of the American College of Cardiology. 23 (3): 617–626. doi:10.1016/0735-1097(94)90745-5. PMID 8113543.
  44. ^ Dejong, J; Cargnomi, A; Bradamante, S; Curello, S; Janssen, M; Pasini, E; Ceconi, C; Bunger, R; Ferrari, R (Jan 1995). "Intermittent v continuous ischernia decelerates adenylate breakdown and prevents norepinephrine release in reperfused rabbit heart". Journal of Molecular and Cellular Cardiology. 27 (1): 659–671. doi:10.1016/S0022-2828(08)80058-2. PMID 7760385.
  45. ^ Ferrari, R. (1996), Heusch, Gerd; Schulz, Rainer (eds.), "Commentary on hibernating myocardium and its clinical relevance", New Paradigms of Coronary Artery Disease, Heidelberg: Steinkopff, pp. 53–55, doi:10.1007/978-3-642-53793-6_17, ISBN 978-3-7985-1059-3, retrieved 2022-07-04
  46. ^ Ferrari, R.; Cargnoni, A.; Bernocchi, P.; Pasini, E.; Curello, S.; Ceconi, C.; Ruigrok, T.J.C. (1996-11-15). "Metabolic Adaptation During a Sequence of No-Flow and Low-Flow Ischemia: A Possible Trigger for Hibernation". Circulation. 94 (10): 2587–2596. doi:10.1161/01.CIR.94.10.2587. ISSN 0009-7322. PMID 8921805.
  47. ^ Ferrari, R.; Ferrari, F.; Benigno, M.; Pepi, P.; Visioli, O. (Sep 1998). "Hibernating myocardium: its pathophysiology and clinical role". Molecular and Cellular Biochemistry. 186 (1–2): 195–199. doi:10.1023/A:1006872827169. ISSN 0300-8177. PMID 9774201. S2CID 37210796.
  48. ^ Ferrari, Robert (1999). "The search for the hibernating myocardium--have we reached the limit?". Cardiovascular Drugs and Therapy. 13 (2): 137–143. doi:10.1023/A:1007788210163. PMID 10372229. S2CID 30606224.
  49. ^ LaCanna, G (2000-08-15). "Sensitivity, specificity, and predictive accuracies of non-invasive tests, singly and in combination, for diagnosis of hibernating myocardium". European Heart Journal. 21 (16): 1358–1367. doi:10.1053/euhj.1999.2038. PMID 10952825.
  50. ^ Rahimtoola, Shahbudin H.; La Canna, Giovanni; Ferrari, Roberto (Mar 2006). "Hibernating Myocardium". Journal of the American College of Cardiology. 47 (5): 978–980. doi:10.1016/j.jacc.2005.11.038. PMID 16516080. S2CID 43552227.
  51. ^ Ferrari, R.; Ceconi, C. (2012-11-01). "Pertinent: Authors' Retrospective". Cardiovascular Research. 96 (2): 204–207. doi:10.1093/cvr/cvs165. ISSN 0008-6363.
  52. ^ Ferrari, R (2001-05-15). "Favouring myocardial viability to necrosis: a challenge in ischaemic heart disease with prognostic complications". European Heart Journal. 22 (10): 803–804. doi:10.1053/euhj.2000.2563. PMID 11350086.
  53. ^ Scarabelli, Tiziano; Stephanou, Anastasis; Rayment, Neil; Pasini, Evasio; Comini, Laura; Curello, Salvatore; Ferrari, Roberto; Knight, Richard; Latchman, David (2001-07-17). "Apoptosis of Endothelial Cells Precedes Myocyte Cell Apoptosis in Ischemia/Reperfusion Injury". Circulation. 104 (3): 253–256. doi:10.1161/01.CIR.104.3.253. ISSN 0009-7322. PMID 11457740. S2CID 6661375.
  54. ^ Ferrari, R (2002-01-01). "Interleukin-6: a neurohumoral predictor of prognosis in patients with heart failure: light and shadow". European Heart Journal. 23 (1): 9–10. doi:10.1053/euhj.2001.3060. PMID 11741356.
  55. ^ Valgimigli, Marco; Agnoletti, Laura; Curello, Salvatore; Comini, Laura; Francolini, Gloria; Mastrorilli, Francesca; Merli, Elisa; Pirani, Roberto; Guardigli, Gabriele; Grigolato, Pier Giovanni; Ferrari, Roberto (2003-01-21). "Serum From Patients With Acute Coronary Syndromes Displays a Proapoptotic Effect on Human Endothelial Cells: A Possible Link to Pan-Coronary Syndromes". Circulation. 107 (2): 264–270. doi:10.1161/01.CIR.0000045665.57256.86. ISSN 0009-7322. PMID 12538426. S2CID 6804985.
  56. ^ EUROPA-PERTINENT Investigators (2003). "PERTINENT--perindopril-thrombosis, inflammation, endothelial dysfunction and neurohormonal activation trial: a sub-study of the EUROPA study". Cardiovascular Drugs and Therapy. 17 (1): 83–91. doi:10.1023/A:1024394610648. PMID 12843690. S2CID 23888783.
  57. ^ Valgimigli, Marco; Ceconi, Claudio; Malagutti, Patrizia; Merli, Elisa; Soukhomovskaia, Olga; Francolini, Gloria; Cicchitelli, Giordano; Olivares, Adriana; Parrinello, Giovanni; Percoco, Gianfranco; Guardigli, Gabriele (2005-02-22). "Tumor Necrosis Factor-α Receptor 1 Is a Major Predictor of Mortality and New-Onset Heart Failure in Patients With Acute Myocardial Infarction: The Cytokine-Activation and Long-Term Prognosis in Myocardial Infarction (C-ALPHA) Study". Circulation. 111 (7): 863–870. doi:10.1161/01.CIR.0000155614.35441.69. ISSN 0009-7322. PMID 15699251. S2CID 7710874.
  58. ^ Ceconi, C; Fox, K; Remme, W; Simoons, M; Bertrand, M; Parrinello, G; Kluft, C; Blann, A; Cokkinos, D; Ferrari, R (2007-01-01). "ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT". Cardiovascular Research. 73 (1): 237–246. doi:10.1016/j.cardiores.2006.10.021. PMID 17140552. S2CID 2783663.
  59. ^ Angelini, Annalisa; Maiolino, Giuseppe; La Canna, Giovanni; Ceconi, Claudio; Calabrese, Fiorella; Pettenazzo, Elena; Valente, Marialuisa; Alfieri, Ottavio; Thiene, Gaetano; Ferrari, Roberto (Apr 2007). "Relevance of apoptosis in influencing recovery of hibernating myocardium". European Journal of Heart Failure. 9 (4): 377–383. doi:10.1016/j.ejheart.2006.09.012. PMID 17127093. S2CID 27926887.
  60. ^ Ferrari, Roberto; Bertrand, Michel E; Remme, Willem J; Simoons, Maarten L; Deckers, Jaap W; Fox, Kim M (Nov 2007). "Insight into ACE inhibition in the prevention of cardiac events in stable coronary artery disease: the EUROPA trial". Expert Review of Cardiovascular Therapy. 5 (6): 1037–1046. doi:10.1586/14779072.5.6.1037. ISSN 1477-9072. PMID 18035919. S2CID 43723509.
  61. ^ Ceconi, Claudio; Fox, Kim M.; Remme, William J.; Simoons, Maarten L.; Deckers, Jaap W.; Bertrand, Michel; Parrinello, Giovanni; Kluft, Cornelius; Blann, Andrew; Cokkinos, Dennis; Ferrari, Roberto (May 2009). "ACE inhibition with perindopril and biomarkers of atherosclerosis and thrombosis: Results from the PERTINENT study". Atherosclerosis. 204 (1): 273–275. doi:10.1016/j.atherosclerosis.2008.08.042. PMID 18950770.
  62. ^ Ferrari, Roberto; Ceconi, Claudio; Campo, Gianluca; Cangiano, Elisa; Cavazza, Caterina; Secchiero, Paola; Tavazzi, Luigi (2009). "Mechanisms of Remodelling A Question of Life (Stem Cell Production) and Death (Myocyte Apoptosis): A Question of Life (Stem Cell Production) and Death (Myocyte Apoptosis)". Circulation Journal. 73 (11): 1973–1982. doi:10.1253/circj.CJ-09-0573. ISSN 1346-9843. PMID 19822975. S2CID 84309718.
  63. ^ Caliceti, C.; Nigro, P.; Rizzo, P.; Ferrari, R. (2014). "ROS, Notch, and Wnt Signaling Pathways: Crosstalk between Three Major Regulators of Cardiovascular Biology". BioMed Research International. 2014: 318714. doi:10.1155/2014/318714. ISSN 2314-6133. PMC 3932294. PMID 24689035.
  64. ^ Ferrari, R.; Rizzo, P. (2014-08-02). "The Notch pathway: a novel target for myocardial remodelling therapy?". European Heart Journal. 35 (32): 2140–2145. doi:10.1093/eurheartj/ehu244. ISSN 0195-668X. PMID 24970336.
  65. ^ Rizzo, Paola; Mele, Donato; Caliceti, Cristiana; Pannella, Micaela; Fortini, Cinzia; Clementz, Anthony George; Morelli, Marco Bruno; Aquila, Giorgio; Ameri, Pietro; Ferrari, Roberto (2015-01-13). "The Role of Notch in the Cardiovascular System: Potential Adverse Effects of Investigational Notch Inhibitors". Frontiers in Oncology. 4: 384. doi:10.3389/fonc.2014.00384. ISSN 2234-943X. PMC 4292456. PMID 25629006.
  66. ^ Rizzo, P.; Ferrari, R. (2015-03-01). "The Notch pathway: a new therapeutic target in atherosclerosis?". European Heart Journal Supplements. 17 (suppl A): A74–A76. doi:10.1093/eurheartj/suv011. ISSN 1520-765X.
  67. ^ Ferrari, Roberto; Malagù, M.; Biscaglia, S.; Fucili, A.; Rizzo, P. (2016). "Remodelling after an Infarct: Crosstalk between Life and Death". Cardiology. 135 (2): 68–76. doi:10.1159/000445882. ISSN 0008-6312. PMID 27270988. S2CID 40446194.
  68. ^ Fox, K. M. (Sep 2003). "Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)". The Lancet. 362 (9386): 782–788. doi:10.1016/S0140-6736(03)14286-9. PMID 13678872. S2CID 25149680.
  69. ^ Ferrari, Roberto; Fox, Kim (2009). "Insight into the Mode of Action of ACE Inhibition in Coronary Artery Disease: The Ultimate 'EUROPA' Story". Drugs. 69 (3): 265–277. doi:10.2165/00003495-200969030-00003. ISSN 0012-6667. PMID 19275271. S2CID 39598433.
  70. ^ "European trial on reduction of cardiac events with perindopril in stable coronary artery disease - EUROPA". American College of Cardiology.
  71. ^ Fox, Kim; Ferrari, Roberto; Tendera, Michal; Steg, Philippe Gabriel; Ford, Ian (Nov 2006). "Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the If inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) Study". American Heart Journal. 152 (5): 860–866. doi:10.1016/j.ahj.2006.01.013. PMID 17070146.
  72. ^ Fox, Kim; Ford, Ian; Steg, P Gabriel; Tendera, Michal; Ferrari, Roberto (Sep 2008). "Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial". The Lancet. 372 (9641): 807–816. doi:10.1016/S0140-6736(08)61170-8. PMID 18757088. S2CID 26282333.
  73. ^ Fox, Kim; Ford, Ian; Steg, P Gabriel; Tendera, Michal; Robertson, Michele; Ferrari, Roberto (Sep 2008). "Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial". The Lancet. 372 (9641): 817–821. doi:10.1016/S0140-6736(08)61171-X. PMID 18757091. S2CID 6481363.
  74. ^ Fox, K.; Ford, I.; Steg, Ph. G.; Tendera, M.; Robertson, M.; Ferrari, R.; on behalf of the BEAUTIFUL Investigators (2009-10-01). "Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial". European Heart Journal. 30 (19): 2337–2345. doi:10.1093/eurheartj/ehp358. ISSN 0195-668X. PMID 19720635.
  75. ^ Swedberg, Karl; Komajda, Michel; Böhm, Michael; Borer, Jeffrey S; Ford, Ian; Dubost-Brama, Ariane; Lerebours, Guy; Tavazzi, Luigi (Sep 2010). "Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study". The Lancet. 376 (9744): 875–885. doi:10.1016/S0140-6736(10)61198-1. PMID 20801500. S2CID 21196422.
  76. ^ Böhm, Michael; Swedberg, Karl; Komajda, Michel; Borer, Jeffrey S; Ford, Ian; Dubost-Brama, Ariane; Lerebours, Guy; Tavazzi, Luigi (Sep 2010). "Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial". The Lancet. 376 (9744): 886–894. doi:10.1016/S0140-6736(10)61259-7. PMID 20801495. S2CID 205959868.
  77. ^ Writing Committee; Smith, S. C.; Collins, A.; Ferrari, R.; Holmes, D. R.; Logstrup, S.; McGhie, D. V.; Ralston, J.; Sacco, R. L.; Stam, H.; Taubert, K. (2012-12-01). "Our time: a call to save preventable death from cardiovascular disease (heart disease and stroke)". European Heart Journal. 33 (23): 2910–2916. doi:10.1093/eurheartj/ehs313. ISSN 0195-668X. PMID 22988314.
  78. ^ Rizzo, Paola; Miele, Lucio; Ferrari, Roberto (2013-08-21). "The Notch pathway: a crossroad between the life and death of the endothelium". European Heart Journal. 34 (32): 2504–2509. doi:10.1093/eurheartj/ehs141. ISSN 1522-9645. PMID 22645188.
  79. ^ Fox, Kim M.; Ferrari, Roberto (Jul 2011). "Heart rate: a forgotten link in coronary artery disease?". Nature Reviews Cardiology. 8 (7): 369–379. doi:10.1038/nrcardio.2011.58. ISSN 1759-5002. PMID 21519356. S2CID 20523105.
  80. ^ Fox, Kim; Ford, Ian; Steg, Philippe Gabriel; Tardif, Jean-Claude; Tendera, Michal; Ferrari, Roberto (Oct 2013). "Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial): A randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical heart failure". American Heart Journal. 166 (4): 654–661.e6. doi:10.1016/j.ahj.2013.06.024. PMID 24093844.
  81. ^ Fox, Kim; Ford, Ian; Steg, Philippe Gabriel; Tardif, Jean-Claude; Tendera, Michal; Ferrari, Roberto; SIGNIFY Investigators (2014-09-18). "Ivabradine in stable coronary artery disease without clinical heart failure". The New England Journal of Medicine. 371 (12): 1091–1099. doi:10.1056/NEJMoa1406430. hdl:20.500.11820/d9aed159-0654-4fa1-a6d9-8c5fb6dd325a. ISSN 1533-4406. PMID 25176136. S2CID 19002896.
  82. ^ Fox, Kim; Ford, Ian; Steg, Philippe Gabriel; Tardif, Jean-Claude; Tendera, Michal; Ferrari, Roberto (2015-09-17). "Bradycardia and atrial fibrillation in patients with stable coronary artery disease treated with ivabradine: an analysis from the SIGNIFY study". European Heart Journal. 36 (46): 3291–3296. doi:10.1093/eurheartj/ehv451. hdl:11392/2349608. ISSN 0195-668X. PMID 26385957.
  83. ^ Ferrari, Roberto; Ford, Ian; Fox, Kim; Challeton, Jean Pascal; Correges, Anne; Tendera, Michal; Widimský, Petr; Danchin, Nicolas (Sep 2020). "Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trial". The Lancet. 396 (10254): 830–838. doi:10.1016/S0140-6736(20)31790-6. hdl:10044/1/82242. PMID 32877651. S2CID 221365071.
Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Roberto_Ferrari_(cardiologist)&oldid=1254963570"